Seroflo Inhaler 50 Mcg (Salmeterol & Fluticasone)

Seroflo Inhaler 50 mcg – Trusted Entry-Level Combination Asthma Therapy Online

For patients with mild-to-moderate persistent asthma who require the additional support of a long-acting bronchodilator alongside their daily anti-inflammatory preventer — but whose condition does not yet warrant the stronger corticosteroid doses reserved for more severe disease — Seroflo Inhaler 50mcg represents a clinically well-positioned, affordable, and practically convenient entry point into combination ICS-LABA therapy.

Delivering fluticasone propionate 50mcg and salmeterol 25mcg per actuation through a compact, familiar pressurised metered dose inhaler, Seroflo Inhaler 50mcg addresses both the inflammatory and bronchospastic dimensions of asthma simultaneously — in a single device, through a single inhalation, twice each day. Manufactured by Cipla — one of India’s most trusted and globally recognised pharmaceutical companies — Seroflo Inhaler 50mcg offers clinically equivalent dual-action respiratory therapy to branded fluticasone-salmeterol combination products at a significantly more accessible and affordable price point.

At our online pharmacy, we stock genuine Seroflo Inhaler 50mcg products, giving patients convenient, discreet, and affordable access to this trusted entry-level combination respiratory therapy.

What Is Seroflo Inhaler 50 mcg?

Seroflo Inhaler 50 mcg is a fixed-dose combination pressurised metered dose inhaler (pMDI) containing fluticasone propionate 50mcg and salmeterol 25mcg per actuation, manufactured by Cipla as a generic equivalent to the globally recognised Seretide 50 Evohaler.

The 50mcg fluticasone dose positions Seroflo Inhaler 50mcg as the lowest available strength within the Seroflo Inhaler range — making it the most appropriate combination inhaler option for patients at the mild end of the persistent asthma spectrum, those new to combination therapy, paediatric patients requiring low-dose ICS coverage alongside long-acting bronchodilator support, or patients being carefully titrated onto the minimum effective combination dose under prescriber guidance.

As a pMDI format, Seroflo Inhaler 50mcg delivers fluticasone and salmeterol as a precisely measured aerosol dose through a hydrofluorocarbon propellant system — using the compact, portable, and widely familiar pressurised inhaler format that remains the most globally recognised and commonly prescribed inhaler device type in respiratory medicine. Full compatibility with spacer devices makes Seroflo Inhaler 50mcg particularly accessible for paediatric patients and adults who benefit from spacer-assisted delivery for improved drug deposition and reduced oropharyngeal side effects.

Read Our Asthma Inhaler Guide:- Asthma Inhalers: Types, Uses, Benefits & Complete Treatment Guide.

How Seroflo Inhaler 50 mcg Works?

Seroflo Inhaler 50 mcg delivers two pharmacologically complementary active ingredients that target the two fundamental pathological processes driving asthma — chronic airway inflammation and bronchospasm — simultaneously and synergistically with every dose.

Fluticasone Propionate 50mcg — Low-Dose ICS Anti-inflammatory Protection

Fluticasone propionate is one of the most potent inhaled corticosteroids available in clinical practice — characterised by exceptionally high glucocorticoid receptor binding affinity and very high lipophilicity that together ensure clinically meaningful anti-inflammatory airway action even at the relatively low 50mcg dose present in Seroflo Inhaler 50mcg.

At the cellular level, fluticasone binds to glucocorticoid receptors within airway epithelial and inflammatory cells — triggering suppression of the inflammatory gene expression that drives eosinophil recruitment, mast cell activation, cytokine release, and mucosal oedema in asthmatic airways. This multi-level anti-inflammatory action progressively reduces the chronic bronchial hypersensitivity that makes asthmatic airways react so dramatically to everyday triggers — building a protective anti-inflammatory baseline that grows stronger with weeks of consistent use.

Fluticasone’s high lipophilicity creates a sustained tissue depot effect within the airway wall — prolonging local anti-inflammatory duration between doses while simultaneously minimising systemic absorption. This means even the low 50mcg dose delivers meaningful, sustained anti-inflammatory protection with a very favourable systemic safety profile — making it particularly appropriate for paediatric patients and those requiring careful minimisation of corticosteroid exposure.

Salmeterol 25mcg — Long-Acting Beta-2 Bronchodilator Support

Salmeterol complements fluticasone’s anti-inflammatory action by providing sustained, twelve-hour bronchodilation from a single dose — keeping airways physically open and relaxed throughout both waking and sleeping hours. Its unique lipophilic side chain anchors it to the beta-2 receptor site in airway smooth muscle, maintaining the bronchodilating signal for twelve hours and enabling the twice-daily dosing schedule that delivers continuous around-the-clock airway protection.

At 25mcg per actuation, salmeterol in Seroflo Inhaler 50mcg delivers the same bronchodilating dose as all other strengths within the Seroflo Inhaler range — meaning the LABA component provides equivalent long-acting airway relaxation regardless of which fluticasone strength is prescribed. It is the fluticasone dose that escalates across the Seroflo strength range — not the salmeterol.

The combination of fluticasone’s progressive anti-inflammatory protection and salmeterol’s sustained bronchodilation produces complementary and synergistic asthma control that is clinically superior to either component used independently — addressing both what makes asthmatic airways inflamed and what makes them narrowed, simultaneously and consistently.

Seroflo Inhaler 50 mcg vs Other Seroflo Inhaler Strengths

Conditions Treated with Seroflo Inhaler 50 mcg:-

Seroflo Inhaler 50 mcg is prescribed for respiratory conditions where low-dose combined anti-inflammatory and long-acting bronchodilator therapy delivers clinically meaningful improvements in symptom control and quality of life:

• Mild Persistent Asthma — The primary indication, providing entry-level combination ICS-LABA therapy for patients with mild but persistent asthma symptoms requiring more than low-dose ICS monotherapy alone
• Paediatric Asthma — The low 50mcg fluticasone dose makes Seroflo Inhaler 50mcg particularly appropriate for older children and adolescents requiring combination therapy at the minimum effective corticosteroid exposure level
• Step-Up from Low-Dose ICS Monotherapy — For patients currently on low-dose fluticasone or beclomethasone alone whose symptoms have progressed beyond single-agent ICS control — representing the first guideline-recommended combination step-up
• Nocturnal Asthma — Salmeterol’s twelve-hour bronchodilation provides reliable overnight airway protection — reducing night-time coughing, breathlessness, and early morning symptom burden
• Exercise-Induced Bronchoconstriction — Regular twice-daily use helps prevent physical activity from triggering acute airway narrowing in susceptible patients
• Allergic Asthma — Low-dose fluticasone addresses allergen-driven airway inflammation while salmeterol maintains consistent bronchodilation throughout trigger exposure periods
• Minimum Effective Combination Dose Titration — For prescribers aiming to achieve adequate asthma control at the lowest possible ICS dose — Seroflo 50mcg represents the starting point for careful combination therapy titration

Benefits of Seroflo Inhaler 50 mcg:-

• Effective dual-action control at the lowest available ICS dose — Combines fluticasone’s potent receptor affinity with salmeterol’s twelve-hour bronchodilation at minimum corticosteroid exposure — maximising efficacy while minimising steroid burden
• Paediatric-appropriate low ICS strength — The 50mcg fluticasone dose is the most appropriate combination inhaler option for children requiring combined ICS-LABA therapy
• Spacer compatibility — Full pMDI spacer compatibility dramatically improves drug delivery in children and patients with poor coordination — a significant advantage over Rotacap formats
• Consistent twelve-hour salmeterol protection — Sustained airway relaxation throughout day and night from twice-daily dosing — regardless of which Seroflo strength is prescribed
• Progressive low-dose anti-inflammatory benefit — Even 50mcg fluticasone builds meaningful airway inflammation control over weeks of consistent use
• Compact and highly portable pMDI format — Fits in any pocket or bag for convenient everyday carry and immediate rescue accessibility
• Familiar and widely accessible device format — The pressurised inhaler is the most globally recognised respiratory device — requiring minimal new technique learning
• Cipla quality at the most affordable Seroflo price — Consistent pharmaceutical standards at the lowest price point within the Seroflo Inhaler range

How to Use Seroflo Inhaler 50 mcg — Step-by-Step?

Without a Spacer (Adults and Older Children with Good Technique):

1. Remove the mouthpiece cap — Remove and inspect the mouthpiece for debris before use
2. Shake vigorously — Shake the Seroflo Inhaler firmly for five seconds to ensure uniform medication dispersion
3. Prime if necessary — Release two test actuations into the air if the inhaler is new or unused for more than five days
4. Breathe out completely — Exhale slowly and fully away from the mouthpiece — never into the device
5. Seal and position — Place the mouthpiece between your teeth, seal your lips firmly, and hold the inhaler upright
6. Press and inhale simultaneously — Begin inhaling slowly and steadily while pressing the canister down firmly once at the very start of inhalation
7. Continue inhaling deeply — Keep breathing in slowly and as deeply as possible after the canister press
8. Hold your breath — Remove the inhaler and hold breath for ten full seconds before exhaling slowly
9. Replace the cap — Always replace the mouthpiece cap after every use
10. Rinse your mouth — Always rinse thoroughly with water and spit after every dose

With a Spacer (Children and Patients Requiring Improved Delivery):

1. Attach Seroflo Inhaler firmly to the spacer inlet connection
2. Shake the assembled inhaler and spacer together for five seconds
3. Breathe out gently away from the spacer mouthpiece or face mask
4. Place lips firmly around the spacer mouthpiece or apply face mask securely
5. Press the Seroflo canister once to release the dose into the spacer chamber
6. Inhale slowly and deeply through the spacer — or allow five to six normal breaths for young children
7. Hold breath for ten seconds where possible before exhaling slowly
8. Rinse mouth after completion — and wipe face gently for young children using face masks

Important Usage Information

Twice Daily Consistency Is Non-Negotiable — Seroflo Inhaler 50 mcg must be taken at consistent twelve-hour intervals — morning and evening — every single day. The anti-inflammatory benefit of fluticasone is entirely dependent on uninterrupted daily use — skipping doses allows inflammation to return.

Never Use as a Rescue Inhaler — Salmeterol’s slow onset of fifteen to thirty minutes means Seroflo Inhaler 50mcg cannot provide adequate rapid relief during acute asthma attacks. Always maintain a separate short-acting salbutamol reliever inhaler for emergency use.

Always Use a Spacer for Young Children — Children using Seroflo Inhaler 50 mcg must always use a compatible spacer with appropriate face mask or mouthpiece — dramatically improving drug delivery efficiency and making consistent dosing accessible for younger patients.

Rinse Mouth After Every Single Dose — Never omit mouth rinsing — even at the low 50mcg ICS dose, fluticasone residue in the mouth and throat can cause oral thrush and hoarseness without this simple protective step.

Never Use Salmeterol Without ICS in Asthma — Seroflo always delivers both components together — never allow standalone LABA use without concurrent ICS coverage in asthma patients under any circumstances.

Consult Prescriber If Symptoms Worsen — Deteriorating asthma control despite consistent Seroflo 50mcg use signals the need for treatment review — stepping up to Seroflo 125mcg or another appropriate therapy may be indicated.

Common Mistakes to Avoid

• Pressing the canister before starting to inhale — Always begin inhaling first — canister press must coincide with the beginning of inhalation
• Inhaling too rapidly — A slow, steady breath maximises lower airway deposition — rapid inhalation causes most aerosol to impact in the throat
• Forgetting the mouth rinse — Oral thrush risk exists even at low ICS doses — always rinse and spit after every dose
• Not using a spacer for children — Children should always use Seroflo with a spacer — never use pMDI alone for young patients
• Stopping treatment when symptom-free — Symptom absence reflects the medication working — never discontinue independently
• Using as emergency rescue — Always maintain a separate short-acting salbutamol reliever for acute episodes
• Not shaking before use — Always shake vigorously before every actuation for accurate, uniform dosing

Frequently Asked Questions?

What is Seroflo Inhaler 50 mcg used for?

Seroflo Inhaler 50 mcg delivers low-dose combined fluticasone and salmeterol therapy for mild persistent asthma — providing dual anti-inflammatory and bronchodilator control through a twice-daily pressurised metered dose inhaler.

Is Seroflo Inhaler 50 mcg suitable for children?

Yes — the low 50 mcg fluticasone dose is the most appropriate Seroflo Inhaler strength for paediatric patients. Always use with a compatible spacer device and confirm suitability with a paediatric respiratory specialist.

Why does Seroflo Inhaler 50 mcg have the same salmeterol dose as higher strengths?

The salmeterol dose — 25mcg per actuation — remains constant across all Seroflo Inhaler strengths. Only the fluticasone dose escalates with higher strengths. The LABA component provides equivalent bronchodilation regardless of which strength is prescribed.

Can Seroflo Inhaler 50 mcg be used with a spacer?

Yes — as a pMDI format, Seroflo Inhaler 50mcg is fully compatible with spacer devices. Spacer use is strongly recommended for all children and beneficial for many adult patients.

When should I step up from Seroflo Inhaler 50 mcg to a higher strength?

If asthma symptoms remain inadequately controlled despite consistent twice-daily use, consult your prescriber — stepping up to Seroflo Inhaler 125mcg may be clinically indicated.

Is Seroflo Inhaler 50 mcg the same as Seretide 50 Evohaler?

Both contain identical active ingredients — fluticasone propionate 50mcg and salmeterol 25mcg per actuation. Seroflo is Cipla’s generic equivalent — clinically equivalent and significantly more affordable than the branded Seretide product.

Medical Disclaimer:-

The information provided on this page is for general informational purposes only and does not constitute medical advice, a clinical diagnosis, or a personalised treatment recommendation. Seroflo Inhaler 50 mcg is a prescription-only medication and must always be used under the direct guidance and supervision of a qualified healthcare professional. If you experience worsening respiratory symptoms, inadequate symptom control, or any unexpected side effects while using Seroflo Inhaler 50mcg, please consult your doctor, respiratory specialist, or pharmacist without delay. Never adjust, discontinue, or substitute your prescribed combination inhaler therapy without first obtaining appropriate professional medical advice.

Related Ingredients:-

Seroflo Multihaler 250 (Salmeterol/Fluticasone)

Seroflo Rotacaps 100 Mcg (Salmeterol & Fluticasone)

Seretide 250 Mcg Evohaler (Salmeterol & Fluticasone)